www.sankyopharma.com
Assay Development and Screening Partner
Sankyo (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED) chose Evotec as a partner to identify small molecule therapeutics for their pharmaceutical discovery projects. Evotec will apply their skills and proprietary technologies in assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with disease targets selected by Sankyo. Compounds identified in screening will be further characterised and prioritised by Evotec for progression into Sankyo's subsequent lead optimization programs.
"This project is an important extension of our lead discovery activities, and we appreciate Evotec's technological capabilities as well as the commitment to the project. We already enjoyed the atmosphere of mutual respect and believe that this collaboration will be successful."
Dr Hideyuki Haruyama, Corporate Officer and General Manager, Research Institute, Sankyo